PMID: 11912359Mar 26, 2002Paper

Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension

Journal of Glaucoma
L J Katz

Abstract

To compare the efficacy and safety of brimonidine-Purite (Alphagan; Allergan, Irvine, CA) 0.15% and 0.2% three times daily with brimonidine (Alphagan) 0.2% three times daily in patients with glaucoma or ocular hypertension. In this 12-month, randomized, multicenter, double-masked, parallel-group study, patients were randomly assigned to receive brimonidine-Purite 0.15% (n = 381), brimonidine-Purite 0.2% (n = 383), or brimonidine 0.2% (n = 383) three times daily. Visits were conducted before the study, at baseline, at weeks 2 and 6, and at months 3, 6, 9, and 12. Diurnal intraocular pressure was measured at 8 am, 10 am, 3 pm, and 5 pm at baseline, week 6, and at months 3, 6, and 12. Intraocular pressure was also measured at 8 and 10 am at week 2 and month 9. Safety was evaluated by adverse events and other ocular and systemic measures. At baseline, mean intraocular pressure was similar in the three treatment groups. During follow-up, there were no statistically significant among-group differences in mean intraocular pressure or mean changes from baseline intraocular pressure (at peak or trough). The difference in mean intraocular pressure between the brimonidine-Purite-0.15% and brimonidine-0.2% treatment group was less than 1 m...Continue Reading

References

Jul 1, 1974·American Journal of Ophthalmology·A R GassetT Miller
Feb 15, 2000·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·D A LeeC Abrams

❮ Previous
Next ❯

Citations

Apr 3, 2004·Advances in Therapy·Thomas MundorfMark B Abelson
Mar 15, 2006·International Ophthalmology·John S CohenLinda J Greff
Dec 12, 2012·International Ophthalmology·María Alejandra CarrascoJorge Oscar Zárate
Apr 3, 2004·American Journal of Ophthalmology·William C StewartJessica N Jenkins
Jul 2, 2003·American Journal of Ophthalmology·Richard G FiscellaJacob Wilensky
Jul 11, 2003·Survey of Ophthalmology·Larry WheelerRonald Lai
Jul 11, 2003·Survey of Ophthalmology·Louis Cantor
Feb 20, 2007·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Leonard Bielory
Aug 24, 2004·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jennifer Q DongScott M Whitcup
Aug 25, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·E Randy CravenUNKNOWN Combigan Study Group
Jul 1, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Ho Yeop YeomGong Je Seong
Aug 17, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Alexander R KentLuanna R Bartholomew
Sep 29, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Chan Yun KimGong Je Seong
Jul 27, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Michael Sullivan-MeeClifford Qualls
Jun 23, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Malik Y Kahook, David A Ammar
Mar 18, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Françoise Brignole-BaudouinChristophe Baudouin
Mar 25, 2008·Therapeutics and Clinical Risk Management·Robert J Noecker
Mar 25, 2008·Therapeutics and Clinical Risk Management·Louis B Cantor
May 31, 2006·Drugs & Aging·Elliott Kanner, James C Tsai
Mar 1, 2012·Expert Opinion on Pharmacotherapy·Anastasios G P KonstasTony Realini
Mar 11, 2005·Expert Opinion on Emerging Drugs·James C Tsai, Elliott M Kanner
Aug 9, 2003·Expert Opinion on Drug Safety·Joel S Schuman
Apr 7, 2010·Expert Opinion on Drug Safety·Mamun Q RahmanDonald M I Montgomery
Sep 13, 2011·Expert Opinion on Drug Delivery·Maurizio RolandoMalik Y Kahook
Mar 17, 2011·Expert Opinion on Emerging Drugs·Alessandro BagnisCarlo E Traverso
Nov 27, 2007·Expert Opinion on Pharmacotherapy·Jess T Whitson
May 28, 2009·Current Medical Research and Opinion·Louis B CantorDavid A Hollander
Feb 11, 2012·Current Medical Research and Opinion·Jin-Wei ChengGuo-Cai Lu
Jul 28, 2011·The Ocular Surface·Charles S TresslerMichael A Lemp
Apr 29, 2011·Experimental Eye Research·Stella Arthur, Louis B Cantor
Sep 4, 2007·American Journal of Ophthalmology·Samin HongSueng-Han Han
Aug 18, 2004·Journal of Cataract and Refractive Surgery·John E ThordsenRichard Stutzman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.